Cargando…

The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design

BACKGROUND: Streptococcus pneumoniae is a globally important pathogen. The Gram-positive diplococcus is a leading cause of pneumonia, otitis media, bacteremia, and meningitis, and antibiotic resistant strains have become increasingly common over recent years. Alanine racemase is a ubiquitous enzyme...

Descripción completa

Detalles Bibliográficos
Autores principales: Im, Hookang, Sharpe, Miriam L, Strych, Ulrich, Davlieva, Milya, Krause, Kurt L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146814/
https://www.ncbi.nlm.nih.gov/pubmed/21612658
http://dx.doi.org/10.1186/1471-2180-11-116
_version_ 1782209240635539456
author Im, Hookang
Sharpe, Miriam L
Strych, Ulrich
Davlieva, Milya
Krause, Kurt L
author_facet Im, Hookang
Sharpe, Miriam L
Strych, Ulrich
Davlieva, Milya
Krause, Kurt L
author_sort Im, Hookang
collection PubMed
description BACKGROUND: Streptococcus pneumoniae is a globally important pathogen. The Gram-positive diplococcus is a leading cause of pneumonia, otitis media, bacteremia, and meningitis, and antibiotic resistant strains have become increasingly common over recent years. Alanine racemase is a ubiquitous enzyme among bacteria and provides the essential cell wall precursor, D-alanine. Since it is absent in humans, this enzyme is an attractive target for the development of drugs against S. pneumoniae and other bacterial pathogens. RESULTS: Here we report the crystal structure of alanine racemase from S. pneumoniae (Alr(SP)). Crystals diffracted to a resolution of 2.0 Å and belong to the space group P3(1)21 with the unit cell parameters a = b = 119.97 Å, c = 118.10 Å, α = β = 90° and γ = 120°. Structural comparisons show that Alr(SP )shares both an overall fold and key active site residues with other bacterial alanine racemases. The active site cavity is similar to other Gram positive alanine racemases, featuring a restricted but conserved entryway. CONCLUSIONS: We have solved the structure of Alr(SP), an essential step towards the development of an accurate pharmacophore model of the enzyme, and an important contribution towards our on-going alanine racemase structure-based drug design project. We have identified three regions on the enzyme that could be targeted for inhibitor design, the active site, the dimer interface, and the active site entryway.
format Online
Article
Text
id pubmed-3146814
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31468142011-07-31 The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design Im, Hookang Sharpe, Miriam L Strych, Ulrich Davlieva, Milya Krause, Kurt L BMC Microbiol Research Article BACKGROUND: Streptococcus pneumoniae is a globally important pathogen. The Gram-positive diplococcus is a leading cause of pneumonia, otitis media, bacteremia, and meningitis, and antibiotic resistant strains have become increasingly common over recent years. Alanine racemase is a ubiquitous enzyme among bacteria and provides the essential cell wall precursor, D-alanine. Since it is absent in humans, this enzyme is an attractive target for the development of drugs against S. pneumoniae and other bacterial pathogens. RESULTS: Here we report the crystal structure of alanine racemase from S. pneumoniae (Alr(SP)). Crystals diffracted to a resolution of 2.0 Å and belong to the space group P3(1)21 with the unit cell parameters a = b = 119.97 Å, c = 118.10 Å, α = β = 90° and γ = 120°. Structural comparisons show that Alr(SP )shares both an overall fold and key active site residues with other bacterial alanine racemases. The active site cavity is similar to other Gram positive alanine racemases, featuring a restricted but conserved entryway. CONCLUSIONS: We have solved the structure of Alr(SP), an essential step towards the development of an accurate pharmacophore model of the enzyme, and an important contribution towards our on-going alanine racemase structure-based drug design project. We have identified three regions on the enzyme that could be targeted for inhibitor design, the active site, the dimer interface, and the active site entryway. BioMed Central 2011-05-25 /pmc/articles/PMC3146814/ /pubmed/21612658 http://dx.doi.org/10.1186/1471-2180-11-116 Text en Copyright ©2011 Im et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Im, Hookang
Sharpe, Miriam L
Strych, Ulrich
Davlieva, Milya
Krause, Kurt L
The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design
title The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design
title_full The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design
title_fullStr The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design
title_full_unstemmed The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design
title_short The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design
title_sort crystal structure of alanine racemase from streptococcus pneumoniae, a target for structure-based drug design
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146814/
https://www.ncbi.nlm.nih.gov/pubmed/21612658
http://dx.doi.org/10.1186/1471-2180-11-116
work_keys_str_mv AT imhookang thecrystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign
AT sharpemiriaml thecrystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign
AT strychulrich thecrystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign
AT davlievamilya thecrystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign
AT krausekurtl thecrystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign
AT imhookang crystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign
AT sharpemiriaml crystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign
AT strychulrich crystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign
AT davlievamilya crystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign
AT krausekurtl crystalstructureofalanineracemasefromstreptococcuspneumoniaeatargetforstructurebaseddrugdesign